2. Food and Drugs Administration. Norvir (Ritonavir). Accessdata.fda.gov. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209512lbl.pdf
3. Maher D, Lee J, Woo P, Zhang X, White P, Yumul R et al. Ritonavir Use in Human Immunodeficiency Virus–Positive Surgical Patients Is Not Associated with an Increase in Postoperative Critical Respiratory Events. Journal of Pain & Palliative Care Pharmacotherapy. 2016;30(1):25-30.
5. Sato A. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies. OncoTargets and Therapy. 2015;8:761-768.
12. Medscape. Norvir (ritonavir) dosing, indications, interactions, adverse effects, and more. 2022. https://reference.medscape.com/drug/norvir-ritonavir-342627
13. Isono M, Sato A, Okubo K, Asano T, Asano T. Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 2016;24(5):327-335.
14. Tseng A, Hughes C, Wu J, Seet J, Phillips E. Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences. Annals of Pharmacotherapy. 2017;51(11):1008-1022.